CardioTech boosts working capital:
This article was originally published in Clinica
CardioTech, which is developing small bore vascular grafts and polymer-based materials, has raised $1.25 million through exercising options on 839,000 of its 1.8 million stock warrants issued in 1998. The Woburn, Massachusetts-based company said that the funds would be applied to marketing for the Vasculink vascular access graft outside the US and on further development of the MyoLink peripheral graft.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.